Identification of peripheral blood test parameters predicting the response to palbociclib and endocrine therapy for metastatic breast cancer: a retrospective study in a single institution
Surgery Today · 2025-02 · 55 (2) · 188-196
DOI: 10.1007/s00595-024-02893-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgery Today, online erschienen am 04.07.2024. Verfasst von Misato Yamamoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Pyridines, Piperazines, Hematologic Tests. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nagoya University.
Abstract (Originalsprache)
Purpose
Cyclin-dependent kinase 4/6 inhibitors have been used in endocrine therapy for patients with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. Although randomized trials have shown that combined therapies prolong progression-free survival (PFS) in comparison to endocrine monotherapy, the predictors of efficacy are unknown. This study aimed to identify the blood test parameters to predict the effects of palbociclib and endocrine therapy.
Methods
Seventy-nine patients treated with palbociclib and endocrine therapy between December 2017 and June 2022 were reviewed. We assessed PFS in patients according to factors evaluated based on patient characteristics and peripheral blood tests.
Results
Patients in the C-reactive protein (CRP)-high, lactate dehydrogenase (LDH)-high, and albumin (Alb)-low groups had significantly shorter PFS than those in the normal group. A multivariate analysis revealed that high LDH and low Alb levels were independent factors that affected PFS. The Alb-low group had an inferior disease control rate. Patients in the CRP-high, LDH-high, and Alb-low groups who received these therapies as first- or second-line treatments showed poor PFS.
Conclusions
Several predictors of the efficacy of palbociclib and endocrine therapy were identified in the peripheral blood test parameters of patients with ER-positive and HER2-negative subtypes of metastatic breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan.
- Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. shibatamasahiro1124@yahoo.co.jp.
- Depatment of Surgery, Nagoya Ekisaikai Hospital, 4-66 Shounen-Cho, Nakagawa-Ku, Nagoya, Aichi, 454-8502, Japan. shibatamasahiro1124@yahoo.co.jp.
- Department of Surgery, Inazawa Municipal Hospital, 100 Numa, Nazuka-Cho, Inazawa, Aichi, 492-8510, Japan.
- Department of Surgery,, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, 3-35 Michishita-Cho, Nakamura-Ku, Nagoya, Aichi, 453-8511, Japan.
Förderung
- Nagoya University
Zitieren
APA
Yamamoto, M., Shibata, M., Tanaka, A., Tsunoda, N., & Masuda, N. (2025). Identification of peripheral blood test parameters predicting the response to palbociclib and endocrine therapy for metastatic breast cancer: a retrospective study in a single institution. Surgery Today, 55(2), 188-196. https://doi.org/10.1007/s00595-024-02893-z
Vancouver
Yamamoto M, Shibata M, Tanaka A, Tsunoda N, Masuda N. Identification of peripheral blood test parameters predicting the response to palbociclib and endocrine therapy for metastatic breast cancer: a retrospective study in a single institution. Surgery Today. 2025;55(2):188-196. doi:10.1007/s00595-024-02893-z
BibTeX
@article{Yamamoto2025,
author = {Yamamoto, Misato and Shibata, Masahiro and Tanaka, Aya and Tsunoda, Nobuyuki and Masuda, Norikazu},
title = {Identification of peripheral blood test parameters predicting the response to palbociclib and endocrine therapy for metastatic breast cancer: a retrospective study in a single institution},
journal = {Surgery Today},
year = {2025},
volume = {55},
number = {2},
pages = {188--196},
doi = {10.1007/s00595-024-02893-z}
}
EUVIMED